Skip to content

Biosimilars Review & Report

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Biosimilar Approval Status
Home
- Home
About BR&R
News and Commentary
BR&R Manufacturer Profiles
- Amneal Biosciences
- Samsung Bioepis
Contact Us

$0.00 0 items

The-Princess-Bridee-vizzini-1

Stanton Mehr December 17, 2019

Published by Stanton Mehr

View all posts by Stanton Mehr

Published December 17, 2019

Post navigation

Previous Post The Baby, Biosimilars, and the Bath Water, Part 2

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Search for:

Recent Posts

Biosimilar Company Acquisitions: Amneal and Sun in Separate Deals Signal More Generic Drug Maker Participation May 4, 2026
More on the Dynamics of the Biosimilar Marketplace May 1, 2026
Market Share vs. ASP: Do Oncology Biosimilar Trends Make Sense? April 29, 2026
Pharmacy’s View on MFN, MFP, and Drinking From the Firehouse April 17, 2026
100% Tariffs Slapped on Pharmaceutical Companies, With Many Exceptions: Circumventing the Supreme Court? April 3, 2026
FDA vs. EMA Biosimilar Approvals, an Update March 30, 2026
Samsung Bioepis, Sandoz Forge Deeper Biosimilar Ties March 19, 2026
As Oncology Biosimilar Acquisition Prices Fall for Hospitals, Biosimilar Adoption Rises March 16, 2026
The FDA’s New Draft Guidance Contributes to Streamlined Biosimilar Development March 12, 2026
Two Leaders’ Views on National PBM Reform: Biosimilar and ERISA Benefits March 9, 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Top Posts & Pages

Biosimilar Approval Status
The Evolution of the Biosimilars Market
When Will a Biosimilar Version of Xolair® be Available?
Amgen’s Version of Adalimumab Deemed “Highly Similar” to Humira®
Supreme Court to Hear Sandoz v. Amgen Arguments on the 180-Day Notification Period
Sandoz Decides Against Marketing Rituximab Biosimilar in US
Biocon and Mylan: The Race to Approve Insulin Glargine Follow-on
A Conversation With Christine M. Simmon, Executive Director, Biosimilars Council and Senior VP, Policy and Strategic Alliances, Association for Accessible Medicines
Part B Biosimilar Sustainability Also in Question
A New Wave of Ustekinumab Biosimilar Launches, Discounted up to 90%

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.

To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

X
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions
Privacy Policy

Copyright

Copyright 2013-2026 by SM Health Communications LLC. All Rights Reserved

Powered by WordPress.com.